Scotiabank upgraded Beam Therapeutics (BEAM) to Outperform from Sector Perform with a $40 price target
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BEAM:
- Beam Therapeutics’ BEAM-302 Shows Promising Phase I/II Results, Earning Buy Rating from Analyst
- Beam Therapeutics’ BEAM-302 Shows Promising Efficacy and Safety in AATD Treatment, Earning Buy Rating
- Beam Therapeutics Reports Positive Phase 1/2 Trial Data
- Beam Therapeutics 16.152K share Secondary priced at $28.48
- Beam Therapeutics announces ‘positive’ data from study of BEAM-302
Questions or Comments about the article? Write to editor@tipranks.com